33
Participants
Start Date
December 18, 2024
Primary Completion Date
December 31, 2029
Study Completion Date
December 31, 2030
Elranatamab
Subcutaneous injection of elranatamab. If patient achieves MRD negative remission, patient would enter treatment-free observation period with MRD monitoring.
RECRUITING
University of California San Diego, La Jolla
University of California, San Diego
OTHER